These results, together with different studies that have shown that co-targeting Bcl-xL and Mcl-1 could be effective in melanoma, non-small cell lung cancer, epithelial tumors of the thymus, and prostate cancer46–50, would indicate that targeting these anti-apoptotic factors is a promising avenue in high-grade gliomas. The gene discussed is BCL2L1; the disease is glioma.